Eupraxia Pharmaceuticals (TSX:EPRX) ROCE %: -58.30% (As of Mar. 2026)


TSX:EPRX Eupraxia Pharmaceuticals Inc TSX:EPRX
37 GF Score
Price C$9.38
! 1 Warning Sign
View Full Analysis

What is Eupraxia Pharmaceuticals ROCE %?

Eupraxia Pharmaceuticals TSX:EPRX +2.85% 37 ROCE % is -58.30% as of Mar. 2026. GuruFocus rates TSX:EPRX with a GF Score™ of 37/100. The stock has 1 warning sign investors should review.

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Eupraxia Pharmaceuticals's annualized ROCE % for the quarter that ended in Mar. 2026 was -58.30%.

Eupraxia Pharmaceuticals  (TSX:EPRX) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Eupraxia Pharmaceuticals ROCE % Related Terms

Eupraxia Pharmaceuticals ROCE % Historical Data

* Premium members only.

The historical data trend for Eupraxia Pharmaceuticals's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Eupraxia Pharmaceuticals ROCE % Chart

Eupraxia Pharmaceuticals Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROCE %
Get a 7-Day Free Trial Premium Member Only -562.13 -96.14 -323.55 -153.86 -68.05

Eupraxia Pharmaceuticals Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROCE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -97.20 -141.66 -46.64 -78.95 -58.30
TSX:EPRX
37GF Score
Eupraxia Pharmaceuticals Inc TSX:EPRX
ROCE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Eupraxia Pharmaceuticals ROCE % Calculation

Eupraxia Pharmaceuticals's annualized ROCE % for the fiscal year that ended in Dec. 2025 is calculated as:

ROCE %=EBIT/( (Capital Employed+Capital Employed)/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(A: Dec. 2025 )  (A: Dec. 2024 )(A: Dec. 2025 )
=-53.231/( ( (49.782 - 4.421) + (118.844 - 7.764) )/ 2 )
=-53.231/( (45.361+111.08)/ 2 )
=-53.231/78.2205
=-68.05 %

Eupraxia Pharmaceuticals's ROCE % of for the quarter that ended in Mar. 2026 is calculated as:

ROCE %=EBIT (1)/( (Capital Employed+Capital Employed)/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=EBIT/( ( (Total Assets - Total Current Liabilities)+(Total Assets - Total Current Liabilities) )/ count )
(Q: Mar. 2026 )  (Q: Dec. 2025 )(Q: Mar. 2026 )
=-87.572/( ( (118.844 - 7.764) + (199.424 - 10.101) )/ 2 )
=-87.572/( ( 111.08 + 189.323 )/ 2 )
=-87.572/150.2015
=-58.30 %

(1) Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about ROCE % →
What does a ROCE % of -58.30% mean?
Eupraxia Pharmaceuticals (TSX:EPRX) has a ROCE % of -58.30% as of Mar. 2026.
Is Eupraxia Pharmaceuticals' ROCE % too high?
Eupraxia Pharmaceuticals' current ROCE % is -58.30%. Overall, Eupraxia Pharmaceuticals has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.
How does Eupraxia Pharmaceuticals' ROCE % compare to VRTX and REGN?
Eupraxia Pharmaceuticals' ROCE % of -58.30% can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROCE % for a Biotechnology company?
A good ROCE % depends on the Biotechnology industry context. However, ROCE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROCE % mean?
A high ROCE % can signal that a stock is expensive relative to its fundamentals. Eupraxia Pharmaceuticals's current ROCE % is -58.30%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Eupraxia Pharmaceuticals stock overvalued right now?
Eupraxia Pharmaceuticals (TSX:EPRX) has a current ROCE % of -58.30%. The current ROCE % is -58.30%. Eupraxia Pharmaceuticals' overall GF Score™ is 37/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROCE % calculated?
ROCE % is calculated from a company's financial statements. For Eupraxia Pharmaceuticals (TSX:EPRX), the current ROCE % is -58.30% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Eupraxia Pharmaceuticals Business Description

Other Exchanges EPRX:USAX43:Germany
Address 201 2067 Cadboro Bay Road, Victoria, BC, CAN, V8R 5G4
Eupraxia Pharmaceuticals Inc is a clinical-stage biotechnology company focused on the development of locally delivered, extended-release alternatives to existing pharmaceuticals. Its product EP-104 is used for the treatment of osteoarthritis and eosinophilic esophagitis symptoms. The company leverages its proprietary Diffusphere technology to optimize drug delivery for applications with unmet medical needs. Currently, the company has two distinct clinical development programs, one targeting EoE and the second targeting chronic Osteoarthritis pain in the knee and has completed a Phase 2b clinical trial with EP-104IAR in knee OA.
37GF Score

Get the complete analysis for TSX:EPRX

ROCE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$9.38
Price